HC Wainwright & Co. Initiates Coverage On Cadrenal Therapeutics with Buy Rating, Announces Price Target of $3
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has initiated coverage on Cadrenal Therapeutics with a Buy rating and set a price target of $3. The company is listed on NASDAQ under the ticker CVKD.

November 20, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cadrenal Therapeutics has been given a Buy rating and a price target of $3 by HC Wainwright & Co. analyst Joseph Pantginis.
The initiation of coverage by an analyst with a Buy rating typically suggests a positive outlook on the stock's future performance. The announcement of a price target provides a specific goal that can influence investor expectations and market sentiment. Given that this is a new coverage, it may attract investor attention and could lead to increased trading volume and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100